sankyo co ltd annual report 2005 it s time to move the next phase our goal becoming a japan based global pharma innovator contents 1 key initiatives as 2 message from president 12 substantial progress toward goals 22 principal products 24 current status of olmesartan and its life cycle management plan 26 risks related business daiichi 32 corporate social responsibility csr 34 members board 36 topics history 38 financial section five year summary 39 review 42 consolidated balance sheets 44 statements income 45 shareholders equity 46 cash flows 47 notes 63 independent auditors 64 subsidiaries 65 network 66 company information 52 cautionary statement with respect forward looking presented in this are on assumptions beliefs light available at present such involve uncertainties that could cause actual results differ expectations overseas
